BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses. METHODS: Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease. RESULTS: Cases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations. CONCLUSION: Exceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses. METHODS: Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease. RESULTS: Cases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations. CONCLUSION: Exceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses. Published by Oxford University Press 2020. This work is written by US Government employees and is in the public domain in the US.
Authors: Neeraj Agarwal; Jordan P McPherson; Hanna Bailey; Sumati Gupta; Theresa L Werner; Guru Reddy; Gajanan Bhat; Erin B Bailey; Sunil Sharma Journal: Cancer Chemother Pharmacol Date: 2015-12-30 Impact factor: 3.333
Authors: P Pautier; V Ribrag; P Duvillard; A Rey; I Elghissassi; I Sillet-Bach; P Kerbrat; F Mayer; A Lesoin; B Brun; H Crouet; J C Barats; P Morice; C Lhommé Journal: Ann Oncol Date: 2007-08-30 Impact factor: 32.976
Authors: Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga Journal: Lancet Oncol Date: 2013-04-18 Impact factor: 41.316
Authors: Matthew I Milowsky; Gopa Iyer; Ashley M Regazzi; Hikmat Al-Ahmadie; Scott R Gerst; Irina Ostrovnaya; Lan L Gellert; Rana Kaplan; Ilana R Garcia-Grossman; Deepa Pendse; Arjun V Balar; Anne Marie Flaherty; Alisa Trout; David B Solit; Dean F Bajorin Journal: BJU Int Date: 2013-04-03 Impact factor: 5.588
Authors: Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella Journal: Blood Adv Date: 2020-10-27
Authors: David A Wheeler; Naoko Takebe; Toshinori Hinoue; Katherine A Hoadley; Maria F Cardenas; Alina M Hamilton; Peter W Laird; Linghua Wang; Adrienne Johnson; Ninad Dewal; Vincent Miller; David Piñeyro; Manuel Castro de Moura; Manel Esteller; Hui Shen; Jean Claude Zenklusen; Roy Tarnuzzer; Lisa M McShane; James V Tricoli; Paul M Williams; Irina Lubensky; Geraldine O'Sullivan-Coyne; Elise C Kohn; Richard F Little; Jeffrey White; Shakun Malik; Lyndsay Harris; Carol Weil; Alice P Chen; Chris Karlovich; Brian Rodgers; Lalitha Shankar; Paula Jacobs; Tracy Nolan; Jianhong Hu; Donna M Muzny; Harshavardhan Doddapaneni; Viktoriya Korchina; Julie Gastier-Foster; Jay Bowen; Kristen Leraas; Elijah F Edmondson; James H Doroshow; Barbara A Conley; S Percy Ivy; Louis M Staudt Journal: Cancer Cell Date: 2020-11-19 Impact factor: 31.743